The ZR75-1 and BT483 cell lines were obtained from the ATCC (Bethesda, MD). MCF7 cells derived from the original University of Michigan stock were kindly provided by Dr. K. Nephew (University of Indiana, Bloomington). Palbociclib and 5FU were purchased from Selleckchem (Houston, TX). All Materials were obtained as described in the references [1 (link)–5 (link)]. Trypsin-EDTA, DMEM, RPMI, penicillin-streptomycin were purchased from GIBCOBRL (GIBCOBRL Life Technologies, Grand Island, NY). Other reagents and performance of experimental procedures were as described [1 (link)–5 (link)]. Antibodies were purchased from Cell Signaling Technology (Danvers, MA); Abgent (San Diego, CA); Novus Biologicals (Centennial, CO); Abcam (Cambridge, UK); and Santa Cruz Biotechnology (Dallas, TX). Specific multiple independent siRNAs to knock down the expression of CD95, FADD, Beclin1, ATG5 AMPKa1, ATM, BIM, BAX, BAK, BID and eIF2α, and scramble control, were purchased from Qiagen (Hilden Germany). Control studies were presented showing on-target specificity of our siRNAs, primary antibodies, and our phospho-specific antibodies to detect both total protein levels and phosphorylated levels of proteins [1 (link)–6 (link)] (Supplementary Figure 5).
Free full text: Click here